Showcases Stock ranks Forex

Iteos Therapeutics Inc (ITOS)
27.01  -0.24 (-0.88%) 08-08 16:00
Open: 27.52 Pre. Close: 27.25
High: 27.52 Low: 26.39
Volume: 203,887 Market Cap: 960M
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 27.542 - 27.681 27.681 - 27.77
Low: 26.064 - 26.245 26.245 - 26.361
Close: 26.745 - 27.024 27.024 - 27.202
Stock Technical Analysis
Target: Six months: 32.76
One year: 38.27
Support: Support1: 23.49
Support2: 20.67
Resistance: Resistance1: 28.05
Resistance2: 32.76
Pivot: 25.78
Moving Averages: MA(5): 26.54
MA(20): 25.44
MA(100): 24.66
MA(250): 29.88
MACD: MACD(12,26): 1.16
Signal(12,26,9): 1.11
%K %D: %K(14,3): 79.36
%D(3): 73.50
RSI: RSI(14): 62.95
52-Week: High: 52.43
Low: 16.21
Change(%): 10.8
Average Vol(K): 3-Month: 453
10-Days: 268
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ ITOS ] has closed below upper band by 19.5%. Bollinger Bands are 40.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Tue, 02 Aug 2022
iTeos to Present at the 2022 Wedbush PacGrow Healthcare Conference -

Sun, 31 Jul 2022
16840 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Purchased by Comerica Bank - Defense World

Wed, 27 Jul 2022
iTeos Therapeutics: Too Many Unknowns (NASDAQ:ITOS) - Seeking Alpha

Tue, 26 Jul 2022
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired by SG Americas Securities LLC - Defense World

Mon, 25 Jul 2022
Head to Head Review: Adverum Biotechnologies (NASDAQ:ADVM) vs. iTeos Therapeutics (NASDAQ:ITOS) - Defense World

Mon, 18 Jul 2022
7549 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Acquired by Oregon Public Employees Retirement Fund - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 35.54
Shares Float (M) 24.22
% Held by Insiders 0.27
% Held by Institutions 105.57
Shares Short (K) 2900
Shares Short Prior Month (K) 2160
Stock Financials
EPS 8.240
Book Value (p.s.) 17.640
Profit Margin 59.85
Operating Margin 77.35
Return on Assets (ttm) 40.6
Return on Equity (ttm) 63.4
Qtrly Rev. Growth
Gross Profit (p.s.) 9.701
Sales Per Share 13.993
EBITDA (p.s.) 10.842
Qtrly Earnings Growth
Operating Cash Flow (M) 503.93
Levered Free Cash Flow (M) 404.19
Stock Valuation
PE Ratio 3.28
PEG Ratio
Price to Book value 1.53
Price to Sales 1.93
Price to Cash Flow 1.90
Stock Dividends
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android